Aduro BioTech Inc (ADRO) Insider Blaine Templeman Sells 10,262 Shares

Aduro BioTech Inc (NASDAQ:ADRO) insider Blaine Templeman sold 10,262 shares of Aduro BioTech stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $5.81, for a total transaction of $59,622.22. Following the sale, the insider now owns 131,119 shares of the company’s stock, valued at $761,801.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Blaine Templeman also recently made the following trade(s):

  • On Thursday, September 13th, Blaine Templeman sold 6,056 shares of Aduro BioTech stock. The shares were sold at an average price of $6.50, for a total transaction of $39,364.00.

Shares of ADRO opened at $6.00 on Thursday. Aduro BioTech Inc has a fifty-two week low of $5.10 and a fifty-two week high of $11.35.

Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $2.64 million during the quarter, compared to analyst estimates of $3.74 million. Aduro BioTech had a negative net margin of 574.11% and a negative return on equity of 44.97%. sell-side analysts forecast that Aduro BioTech Inc will post -1.25 EPS for the current fiscal year.

Several equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research report on Friday, August 31st. ValuEngine upgraded shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 30th. Canaccord Genuity reiterated a “buy” rating and set a $30.00 target price on shares of Aduro BioTech in a research report on Thursday, August 2nd. Bank of America dropped their target price on shares of Aduro BioTech from $8.00 to $6.00 and set an “underperform” rating for the company in a research report on Thursday, August 2nd. Finally, HC Wainwright set a $10.00 target price on shares of Aduro BioTech and gave the company a “buy” rating in a research report on Thursday, August 2nd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $13.67.

Several institutional investors and hedge funds have recently made changes to their positions in ADRO. Capital Fund Management S.A. bought a new stake in shares of Aduro BioTech in the 2nd quarter worth approximately $130,000. Sofinnova Ventures Inc bought a new stake in shares of Aduro BioTech in the 1st quarter worth approximately $155,000. Legal & General Group Plc lifted its holdings in shares of Aduro BioTech by 105.3% in the 1st quarter. Legal & General Group Plc now owns 22,233 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 11,405 shares during the last quarter. MetLife Investment Advisors LLC lifted its holdings in shares of Aduro BioTech by 70.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 31,799 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 13,156 shares during the last quarter. Finally, DRW Securities LLC lifted its holdings in shares of Aduro BioTech by 160.0% in the 1st quarter. DRW Securities LLC now owns 26,000 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 16,000 shares during the last quarter. Hedge funds and other institutional investors own 49.00% of the company’s stock.

Aduro BioTech Company Profile

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Featured Story: Trading Strategy Methods and Types

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply